Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies The ...

CTN has been operating several older UHF DTV transmitters that were in need of replacement and inked a contract with Comark to replace the six systems with Parallax transmitters. All the new ...

Anne Palmer, a CTN rider, falls into the 11% that ride more than 10 miles. She disagrees with Clupper and said her fare increase will be drastic. Palmer lives outside Fort Wayne city limits and ...